JÃ¶rg H W Distler

List of Publications by Year
in descending order

224 papers	30,349 citations	10351 72 h-index	5364 164 g-index
225 all docs	225 docs citations	225 times ranked	42910 citing authors

#	Article	IF	Citations
1	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. Scientific Reports, 2021, 11, 1.	1.6	9,439
2	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
3	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.5	794
4	Activation of canonical Wnt signalling is required for TGF-Î²-mediated fibrosis. Nature Communications, 2012, 3, 735.	5.8	649
5	MicroRNAâ€29, a key regulator of collagen expression in systemic sclerosis. Arthritis and Rheumatism, 2010, 62, 1733-1743.	6.7	470
6	Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1897-1905.	0.5	410
7	The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2892-2897.	3.3	368
8	Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis and Rheumatism, 2007, 56, 311-322.	6.7	358
9	Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Annals of the Rheumatic Diseases, 2015, 74, 1188-1194.	0.5	340
10	Shared and distinct mechanisms of fibrosis. Nature Reviews Rheumatology, 2019, 15, 705-730.	3.5	331
11	Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis. Circulation Research, 2004, 95, 109-116.	2.0	276
12	Orphan nuclear receptor NR4A1 regulates transforming growth factor-Î² signaling and fibrosis. Nature Medicine, 2015, 21, 150-158.	15.2	267
13	Evidence of innate lymphoid cell redundancy in humans. Nature Immunology, 2016, 17, 1291-1299.	7.0	260
14	Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nature Communications, 2017, 8, 1130.	5.8	245
15	Platelet-derived serotonin links vascular disease and tissue fibrosis. Journal of Experimental Medicine, 2011, 208, 961-972.	4.2	222
16	Microparticles as regulators of inflammation: Novel players of cellular crosstalk in the rheumatic diseases. Arthritis and Rheumatism, 2005, 52, 3337-3348.	6.7	215
17	Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis. PLoS Genetics, 2011, 7, e1002091.	1.5	205
18	Targeting TGF-Î² signaling for the treatment of fibrosis. Matrix Biology, 2018, 68-69, 8-27.	1.5	196

#	Article	IF	Citations
19	Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis and Rheumatism, 2009, 60, 219-224.	6.7	187
20	Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	2.6	182
21	Dual inhibition of câ€abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB Journal, 2008, 22, 2214-2222.	0.2	179
22	Î²-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 761-767.	0.5	174
23	Hypoxiaâ€induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis and Rheumatism, 2007, 56, 4203-4215.	6.7	168
24	The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 1232-1239.	0.5	166
25	Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2019, 54, 1900161.	3.1	164
26	Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 1468-1476.	6.7	158
27	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS ONE, 2016, 11, e0163894.	1.1	158
28	Microparticles as mediators of cellular cross-talk in inflammatory disease. Autoimmunity, 2006, 39, 683-690.	1.2	154
29	Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 883-890.	0.5	154
30	Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycinâ€induced skin fibrosis. Arthritis and Rheumatism, 2007, 56, 2755-2764.	6.7	153
31	Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1941-1948.	0.5	149
32	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Annals of the Rheumatic Diseases, 2019, 78, 979-987.	0.5	142
33	Animal models of systemic sclerosis: Prospects and limitations. Arthritis and Rheumatism, 2010, 62, 2831-2844.	6.7	135
34	Predictors of progression in systemic sclerosis patients with interstitial lung disease. European Respiratory Journal, 2020, 55, 1902026.	3.1	134
35	Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis and Rheumatism, 2012, 64, 2724-2733.	6.7	133
36	Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis and Rheumatism, 2005, 52, 856-864.	6.7	127

#	Article	IF	Citations
37	PU.1 controls fibroblast polarization and tissue fibrosis. Nature, 2019, 566, 344-349.	13.7	121
38	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	1.0	118
39	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respiratory Medicine,the, 2021, 9, 96-106.	5.2	118
40	Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 1304-1310.	0.5	116
41	JAKâ€2 as a novel mediator of the profibrotic effects of transforming growth factor Î² in systemic sclerosis. Arthritis and Rheumatism, 2012, 64, 3006-3015.	6.7	115
42	Sirt1 regulates canonical TGF-Î² signalling to control fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 226-233.	0.5	115
43	Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis. Arthritis and Rheumatism, 2008, 58, 1475-1484.	6.7	111
44	Vitamin D receptor regulates TGF-Î² signalling in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, e20-e20.	0.5	111
45	Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Annals of the Rheumatic Diseases, 2020, 79, 1485-1491.	0.5	111
46	Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis and Rheumatism, 2011, 63, 1396-1404.	6.7	107
47	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 2017, 76, 1207-1218.	0.5	107
48	The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis and Rheumatism, 2009, 60, 1129-1136.	6.7	106
49	Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis. Circulation, 2009, 120, 2367-2376.	1.6	105
50	Tyrosine kinase signaling in fibrotic disorders. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 897-904.	1.8	103
51	Rhoâ€associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis and Rheumatism, 2008, 58, 2553-2564.	6.7	102
52	Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 10-23.	6.7	101
53	Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis and Rheumatism, 2009, 60, 1519-1529.	6.7	100
54	WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. Journal of Bone and Mineral Research, 2012, 27, 575-585.	3.1	100

#	Article	IF	Citations
55	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications, 2019, 10, 4955.	5.8	100
56	Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Research and Therapy, 2009, 11, 220.	1.6	99
57	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Human Molecular Genetics, 2012, 21, 2825-2835.	1.4	98
58	Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Annals of the Rheumatic Diseases, 2013, 72, 1255-1258.	0.5	98
59	Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss. Annals of the Rheumatic Diseases, 2016, 75, 1203-1210.	0.5	98
60	The transcription factor Fraâ€2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis and Rheumatism, 2010, 62, 280-290.	6.7	97
61	Inhibition of glycogen synthase kinase 3Â induces dermal fibrosis by activation of the canonical Wnt pathway. Annals of the Rheumatic Diseases, 2011, 70, 2191-2198.	0.5	96
62	Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 1382-1387.	0.5	93
63	Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Annals of the Rheumatic Diseases, 2013, 72, 614-620.	0.5	93
64	Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFÎ² signalling. Annals of the Rheumatic Diseases, 2015, 74, 1408-1416.	0.5	92
65	The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis and Rheumatism, 2008, 58, 2845-2853.	6.7	91
66	Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis and Rheumatism, 2006, 54, 214-225.	6.7	89
67	The tyrosine phosphatase SHP2 controls TGFÎ²-induced STAT3 signaling to regulate fibroblast activation and fibrosis. Nature Communications, 2018, 9, 3259.	5.8	89
68	Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 1545-1551.	0.5	87
69	Microparticles stimulate the synthesis of prostaglandin E₂ via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. Arthritis and Rheumatism, 2007, 56, 3564-3574.	6.7	82
70	Inhibition of activator protein 1 signaling abrogates transforming growth factor Î²â€"mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis and Rheumatism, 2012, 64, 1642-1652.	6.7	81
71	Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 623-626.	0.5	78
72	TGF-Î²â€"induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. Journal of Clinical Investigation, 2020, 130, 2347-2363.	3.9	76

#	ARTICLE	IF	CITATIONS
73	Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 137-149.	2.9	75
74	A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Human Molecular Genetics, 2012, 21, 926-933.	1.4	74
75	Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 1019-1026.	0.5	74
76	Cutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis. Journal of Immunology, 2018, 200, 1249-1254.	0.4	74
77	Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 800-809.	6.7	73
78	Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 785-789.	0.5	73
79	Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. Annals of the Rheumatic Diseases, 2013, 72, 1575-1580.	0.5	69
80	Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 1880-1887.	0.5	69
81	Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis and Rheumatism, 2010, 62, 3467-3476.	6.7	67
82	Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Annals of the Rheumatic Diseases, 2017, 76, 1133-1141.	0.5	66
83	Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 257-267.	2.9	62
84	Autophagy. Autophagy, 2013, 9, 1253-1255.	4.3	61
85	Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Annals of the Rheumatic Diseases, 2015, 74, 1621-1625.	0.5	60
86	The transcription factor JunD mediates transforming growth factor Â-induced fibroblast activation and fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 1320-1326.	0.5	59
87	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Annals of the Rheumatic Diseases, 2016, 75, 1285-1292.	0.5	56
88	The role of membrane lipids in the induction of macrophage apoptosis by microparticles. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 363-374.	2.2	54
89	The Fra-2 transgenic mouse model of systemic sclerosis. Vascular Pharmacology, 2013, 58, 194-201.	1.0	54
90	Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 737-745.	0.5	53

#	Article	IF	Citations
91	Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood, 2012, 120, 2909-2917.	0.6	53
92	The transcription factor GLI2 as a downstream mediator of transforming growth factor-Î²-induced fibroblast activation in SSc. Annals of the Rheumatic Diseases, 2017, 76, 756-764.	0.5	53
93	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 2018, 57, 370-381.	0.9	53
94	New insight on the Xq28 association with systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 2032-2038.	0.5	52
95	S100A4 amplifies TGF-Î²-induced fibroblast activation in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 1748-1755.	0.5	52
96	Canonical Wnt signaling in systemic sclerosis. Laboratory Investigation, 2016, 96, 151-155.	1.7	52
97	Long noncoding RNA H19X is a key mediator of TGF-Î²â€"driven fibrosis. Journal of Clinical Investigation, 2020, 130, 4888-4905.	3.9	52
98	Nucleofection: a new, highly efficient transfection method for primary human keratinocytes*. Experimental Dermatology, 2005, 14, 315-320.	1.4	51
99	The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 150-158.	0.5	51
100	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Annals of the Rheumatic Diseases, 2018, 77, 563-570.	0.5	50
101	Canonical <scp>Wnt</scp> signalling as a key regulator of fibrogenesis â€" implications for targeted therapies?. Experimental Dermatology, 2013, 22, 710-713.	1.4	49
102	Innovative antifibrotic therapies in systemic sclerosis. Current Opinion in Rheumatology, 2012, 24, 274-280.	2.0	48
103	Brief Report: <i>IRF4</i> Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Crossâ€Disease Metaâ€Analysis of Genomeâ€Wide Association Studies. Arthritis and Rheumatology, 2016, 68, 2338-2344.	2.9	46
104	68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. Lancet Rheumatology, The, 2021, 3, e185-e194.	2.2	46
105	Microparticles stimulate angiogenesis by inducing ELR+ CXC-chemokines in synovial fibroblasts. Journal of Cellular and Molecular Medicine, 2011, 15, 756-762.	1.6	45
106	Inhibition of casein kinase II reduces TGFÎ² induced fibroblast activation and ameliorates experimental fibrosis. Annals of the Rheumatic Diseases, 2015, 74, 936-943.	0.5	45
107	Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. Annals of the Rheumatic Diseases, 2016, 75, 303-310.	0.5	45
108	Nintedanib in Patients With Autoimmune Diseaseâ€"Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the <scp>INBUILD</scp> Trial. Arthritis and Rheumatology, 2022, 74, 1039-1047.	2.9	44

#	Article	IF	Citations
109	Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis and Rheumatism, 2008, 58, 2538-2542.	6.7	43
110	Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials. Current Rheumatology Reports, 2011, 13, 21-27.	2.1	41
111	Emerging strategies for treatment of systemic sclerosis. Journal of Scleroderma and Related Disorders, 2016, 1, 186-193.	1.0	41
112	Influence of<i>TYK2</i>in systemic sclerosis susceptibility: a new<i>locus</i>in the IL-12 pathway. Annals of the Rheumatic Diseases, 2016, 75, 1521-1526.	0.5	41
113	JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. Annals of the Rheumatic Diseases, 2017, 76, 1467-1475.	0.5	41
114	Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial. Arthritis Research and Therapy, 2021, 23, 112.	1.6	40
115	TGFÎ² promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy. Nature Communications, 2021, 12, 4404.	5.8	40
116	Endothelial progenitor cells: Novel players in the pathogenesis of rheumatic diseases. Arthritis and Rheumatism, 2009, 60, 3168-3179.	6.7	39
117	Cardiomyopathy in Murine Models of Systemic Sclerosis. Arthritis and Rheumatology, 2015, 67, 508-516.	2.9	39
118	Cellular and molecular mechanisms in fibrosis. Experimental Dermatology, 2021, 30, 121-131.	1.4	39
119	The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis. PLoS ONE, 2013, 8, e54419.	1.1	38
120	Tribbles homologue 3 stimulates canonical TGF-Î² signalling to regulate fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 609-616.	0.5	38
121	Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clinical Rheumatology, 2019, 38, 2673-2681.	1.0	38
122	Induction of apoptosis in circulating angiogenic cells by microparticles. Arthritis and Rheumatism, 2011, 63, 2067-2077.	6.7	36
123	Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 744-751.	0.5	36
124	Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. Journal of Controlled Release, 2019, 310, 198-208.	4.8	36
125	Stimulatory autoantibodies to plateletâ€derived growth factor receptors in systemic sclerosis: What functional autoimmunity could learn from receptor biology. Arthritis and Rheumatism, 2009, 60, 907-911.	6.7	35
126	The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 1081-1087.	0.5	35

#	Article	IF	Citations
127	Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 1089-1098.	0.5	35
128	Influence of the <i>IL6</i> Gene in Susceptibility to Systemic Sclerosis. Journal of Rheumatology, 2012, 39, 2294-2302.	1.0	34
129	Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. Annals of the Rheumatic Diseases, 2018, 77, 459-459.	0.5	33
130	Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Annals of the Rheumatic Diseases, 2014, 73, 1264-1268.	0.5	32
131	Epigenetic factors as drivers of fibrosis in systemic sclerosis. Epigenomics, 2017, 9, 463-477.	1.0	32
132	Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs. Annals of the Rheumatic Diseases, 2019, 78, 1686-1692.	0.5	32
133	Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 1895-1899.	0.5	31
134	Rationale for the evaluation of nintedanib as a treatment for systemic sclerosisâ€“associated interstitial lung disease. Journal of Scleroderma and Related Disorders, 2019, 4, 212-218.	1.0	31
135	Targeting of <scp>NADPH</scp> oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis. Experimental Dermatology, 2017, 26, 73-81.	1.4	30
136	Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis. Annals of the Rheumatic Diseases, 2016, 75, 2037-2044.	0.5	29
137	Inhibition of sumoylation prevents experimental fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 1904-1908.	0.5	28
138	Combined Inhibition of c-Abl and PDGF Receptors for Prevention and Treatment of Murine Sclerodermatous Chronic Graft-versus-Host Disease. American Journal of Pathology, 2012, 181, 1672-1680.	1.9	28
139	Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Annals of the Rheumatic Diseases, 2015, 74, 1317-1324.	0.5	28
140	Activating transcription factor 3 regulates canonical TGFÎ² signalling in systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 586-592.	0.5	28
141	Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2017, 76, 244-251.	0.5	28
142	Microparticles and their roles in inflammatory arthritides. Nature Reviews Rheumatology, 2010, 6, 385-386.	3.5	27
143	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology, 2020, 59, 1684-1694.	0.9	27
144	Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1. Annals of the Rheumatic Diseases, 2012, 71, 2051-2054.	0.5	26

#	Article	IF	Citations
145	Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. Annals of the Rheumatic Diseases, 2014, 73, 624-627.	0.5	26
146	Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis. Science Translational Medicine, 2020, 12, .	5.8	26
147	Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis. Archives of Dermatological Research, 2013, 305, 1-8.	1.1	25
148	Tie2 as a novel key factor of microangiopathy in systemic sclerosis. Arthritis Research and Therapy, 2017, 19, 105.	1.6	25
149	Morphogen Pathways in Systemic Sclerosis. Current Rheumatology Reports, 2013, 15, 299.	2.1	23
150	Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS ONE, 2020, 15, e0229445.	1.1	23
151	Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma. Annals of the Rheumatic Diseases, 2021, 80, 920-929.	0.5	23
152	Bucillamine Induces the Synthesis of Vascular Endothelial Growth Factor Dose-Dependently in Systemic Sclerosis Fibroblasts via Nuclear Factor-Î°B and Simian Virus 40 Promoter Factor 1 Pathways. Molecular Pharmacology, 2004, 65, 389-399.	1.0	22
153	Decreased lymphatic vessel counts in patients with systemic sclerosis: Association with fingertip ulcers. Arthritis and Rheumatism, 2010, 62, 1513-1522.	6.7	22
154	Activation of pregnane X receptor inhibits experimental dermal fibrosis. Annals of the Rheumatic Diseases, 2013, 72, 621-625.	0.5	22
155	Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling. Annals of the Rheumatic Diseases, 2017, 76, 773-778.	0.5	22
156	Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. Annals of the Rheumatic Diseases, 2011, 70, 1197-1202.	0.5	21
157	Nintedanib in Patients With Systemic Sclerosisâ€"Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. Arthritis and Rheumatology, 2022, 74, 518-526.	2.9	21
158	Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Annals of the Rheumatic Diseases, 2013, 72, 2039-2046.	0.5	20
159	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology, 2022, 61, 4786-4796.	0.9	20
160	PGC-1Î± regulates autophagy to promote fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2020, 79, 1227-1233.	0.5	19
161	Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse. British Journal of Pharmacology, 2020, 177, 4296-4309.	2.7	19
162	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. Rheumatology, 2015, 54, kev260.	0.9	17

#	Article	IF	Citations
163	From pathogenesis to therapy â€“ Perspective on treatment strategies in fibrotic diseases. Pharmacological Research, 2015, 100, 93-100.	3.1	17
164	Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts. Journal of Investigative Dermatology, 2019, 139, 439-447.	0.3	17
165	Patient's Perception of Digital Symptom Assessment Technologies in Rheumatology: Results From a Multicentre Study. Frontiers in Public Health, 2022, 10, 844669.	1.3	17
166	Novel Treatment Approaches to Fibrosis in Scleroderma. Rheumatic Disease Clinics of North America, 2008, 34, 145-159.	0.8	16
167	Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?. Current Opinion in Pharmacology, 2013, 13, 455-462.	1.7	16
168	Acyltransferase skinny hedgehog regulates TGFÎ²-dependent fibroblast activation in SSc. Annals of the Rheumatic Diseases, 2019, 78, 1269-1273.	0.5	16
169	Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation. Journal of Experimental Medicine, 2021, 218, .	4.2	16
170	Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?. Annals of the Rheumatic Diseases, 2007, 66, 836-836.	0.5	15
171	NR4A1 Regulates Motility of Osteoclast Precursors and Serves as Target for the Modulation of Systemic Bone Turnover. Journal of Bone and Mineral Research, 2018, 33, 2035-2047.	3.1	15
172	Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis. Annals of the Rheumatic Diseases, 2021, 80, e87-e87.	0.5	15
173	Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblastâ€“dependent osteoclastogenesis. Arthritis and Rheumatism, 2009, 60, 3663-3675.	6.7	14
174	Updates on animal models of systemic sclerosis. Journal of Scleroderma and Related Disorders, 2016, 1, 266-276.	1.0	14
175	Regulation of Fibroblast Apoptosis and Proliferation by Micro RNA â€125b in Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 2068-2080.	2.9	14
176	LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis. Clinical and Translational Medicine, 2022, 12, e711.	1.7	14
177	The Nuclear Receptor Constitutive Androstane Receptor/NR1I3 Enhances the Profibrotic Effects of Transforming Growth Factor Î² and Contributes to the Development of Experimental Dermal Fibrosis. Arthritis and Rheumatology, 2014, 66, 3140-3150.	2.9	13
178	Tocilizumab for systemic sclerosis: implications for future trials. Lancet, The, 2016, 387, 2580-2581.	6.3	13
179	Innate lymphoid cells and fibrotic regulation. Immunology Letters, 2018, 195, 38-44.	1.1	13
180	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. Annals of the Rheumatic Diseases, 2019, 78, 1681-1685.	0.5	13

#	Article	IF	Citations
181	Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1385-1395.	2.9	13
182	Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. Lancet Rheumatology, The, 2021, 3, e175-e184.	2.2	13
183	Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis. Frontiers in Cell and Developmental Biology, 2021, 9, 681061.	1.8	13
184	Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. Clinical and Experimental Rheumatology, 2015, 33, S75-9.	0.4	13
185	Mitogen-activated protein kinase 2 regulates physiological and pathological bone turnover. Journal of Bone and Mineral Research, 2013, 28, 936-947.	3.1	12
186	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 626-628.	0.5	12
187	Platelet Phagocytosis via Pâ€selectin Glycoprotein Ligand 1 and Accumulation of Microparticles in Systemic Sclerosis. Arthritis and Rheumatology, 2022, 74, 318-328.	2.9	12
188	Lack of inhibitory effects of the antiâ€fibrotic drug imatinib on endothelial cell functions <i>in vitro</i> and <i>in vivo</i>. Journal of Cellular and Molecular Medicine, 2009, 13, 4185-4191.	1.6	11
189	Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease. Blood, 2021, 137, 2403-2416.	0.6	11
190	microRNA-145 mediates xylosyltransferase-I induction in myofibroblasts via suppression of transcription factor KLF4. Biochemical and Biophysical Research Communications, 2020, 523, 1001-1006.	1.0	10
191	Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 989.	2.2	9
192	An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod. Arthritis Research and Therapy, 2021, 23, 204.	1.6	8
193	Changing paradigms in spondylarthritis: The myofibroblast signature. Arthritis and Rheumatism, 2013, 65, 24-27.	6.7	7
194	Comment on: â€˜Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteriaâ€™ by Greco et al. Annals of the Rheumatic Diseases, 2020, 79, e85-e85.	0.5	7
195	The Î±7 Nicotinic Acetylcholine Receptor: A Promising Target for the Treatment of Fibrotic Skin Disorders. Journal of Investigative Dermatology, 2020, 140, 2371-2379.	0.3	7
196	The role of antifibrotics in the treatment of rheumatoid arthritisâ€“associated interstitial lung disease. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210744.	1.2	7
197	Therapeutic molecular targets of SSc-ILD. Journal of Scleroderma and Related Disorders, 2020, 5, 17-30.	1.0	6
198	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology, 2022, 61, 4035-4046.	0.9	6

#	ARTICLE	IF	CITATIONS
199	cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis. Rheumatology, 2020, 59, 3939-3951.	0.9	5
200	Response to: â€˜Correspondence on â€˜Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosisâ€™â€™ by Jeny<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e242-e242.	0.5	5
201	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines, 2021, 9, 650.	1.4	5
202	Impaired Mitochondrial Transcription Factor A Expression Promotes Mitochondrial Damage to Drive Fibroblast Activation and Fibrosis in Systemic Sclerosis. Arthritis and Rheumatology, 2022, 74, 871-881.	2.9	5
203	Mouse Models of Skin Fibrosis. Methods in Molecular Biology, 2021, 2299, 371-383.	0.4	4
204	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. Clinical and Experimental Rheumatology, 2015, 33, S31-5.	0.4	4
205	X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc). Annals of the Rheumatic Diseases, 2021, 80, 1048-1056.	0.5	3
206	The scientific basis for novel treatments of systemic sclerosis. F1000 Medicine Reports, 2009, 1, .	2.9	3
207	The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. Clinical and Experimental Rheumatology, 2021, 39, 134-141.	0.4	3
208	Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis. Nature Clinical Practice Rheumatology, 2008, 4, 160-164.	3.2	2
209	Possible adaptations of vascularised human skin equivalents to include rare cell populations and study fibroblast heterogeneity. Response to: â€˜In search for the ideal anatomical composition of vascularised human skin equivalents for systemic sclerosis translational research: should we recruit the telocytes?â€™ by Manetti and Matucci-Cerinic. Annals of the Rheumatic Diseases, 2019, 80, annrheumdis-2019-216393.	0.5	1
210	Reply. Arthritis and Rheumatology, 2021, 73, 179-180.	2.9	1
211	Overview of Animal Models. , 2017, , 281-293.		1
212	Epigenetic profiling of twins identify repression of KLF4 as a novel pathomechanism in systemic sclerosis. Annals of the Rheumatic Diseases, 2022, 81, 151-152.	0.5	1
213	The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 134-141.	0.4	1
214	Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects. Respiratory Research, 2022, 23, .	1.4	1
215	A8.3â€…Deficit of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNFtg Mouse Model. Annals of the Rheumatic Diseases, 2013, 72, A58.1-A58.	0.5	0
216	A3.19â€…mIR-193B induces UPA in SSC and contributes to the proliferative vasculopathy via uPAR independent pathways. Annals of the Rheumatic Diseases, 2014, 73, A49.2-A49.	0.5	0

#	Article	IF	Citations
217	SAT0271â€…RELATIONSHIP BETWEEN ANTI-MDA5 ANTIBODIES AND CANCER: RETROSPECTIVE ANALYSIS OF AN INTERNATIONAL AND MULTIDISCIPLINARY COHORT. , 2019, , .		0
218	SAT0001â€…FOSL-2 IS A REPRESSOR OF FOXP3 EXPRESSION DURING TREG DEVELOPMENT AND CONTROLS AUTOIMMUNITY. , 2019, , .		0
219	OP0184â€…PROFIBROTIC LNCRNA H19X: UNRAVELLING THE EFFECTS ON CHROMATIN REMODELING IN SYSTEMIC SCLEROSIS FIBROBLASTS. , 2019, , .		0
220	Quantification of 68Ga-FAPI-04 in systemic sclerosis-associated interstitial lung disease â€“ Authors' reply. Lancet Rheumatology, The, 2021, 3, e475-e477.	2.2	0
221	Antiâ€Fibrotic Effect of Ajulemic Acid in Bleomycinâ€Induced Lung Fibrosis. FASEB Journal, 2015, 29, LB744.	0.2	0
222	Purinergic signaling in systemic sclerosis. Rheumatology, 2021, , .	0.9	0
223	Genetic Associations of Nonâ€“Major Histocompatibility Complex Susceptibility Loci with Systemic Sclerosis in a Han Chinese Population. Journal of Investigative Dermatology, 2022, 142, 2039-2042.e7.	0.3	0
224	Deciphering Pro-angiogenic Transcription Factor Profiles in Hypoxic Human Endothelial Cells by Combined Bioinformatics and in vitro Modeling. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0